Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma

Inclusion Criteria: * Age \> 18 years * Histologically and/or cytologically confirmed adenocarcinoma of the pancreas, T1-4, N0-1, M0. Patients should have disease for which combined modality therapy is indicated. * Performance status 0-2 * Life expectancy \> 3 months * Adequate hematologic, renal, hepatic function * Calculated creatinine Cl \> 50 mL/min * Use of effective means of contraception in patients of child-bearing potential. Exclusion Criteria: * No prior therapy for pancreatic cancer * Previous treatment with bevacizumab or erlotinib * Evidence of duodenal invasion or gastric outlet obstruction * Presence of bleeding diathesis or coagulopathy * History or prior arterial thrombotic event * Conditions leading to inadequate gastrointestinal tract absorption * Poorly controlled diarrhea . * Presence of baseline proteinuria or renal dysfunction (CrCl \< 50 (Cockcroft-Gault equation) * Inadequately controlled hypertension * New York Heart Association (NYHA) Grade II or greater congestive heart failure * Clinically significant peripheral vascular disease * Presence of central nervous system or brain metastases * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study * Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0 * Pregnant or lactating females * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0 * Serious, non-healing wound, ulcer, or bone fracture * Inability to comply with study and/or follow-up procedures * Treatment for other carcinomas within the last five years, except cured non-melanoma skin cancer, curatively treated in-situ cervical cancer, or localized prostate cancer with a current PSA of \<1.0 mg/dL on 2 successive evaluations, at least 3 months apart, with the most recent evaluation no more than 4 weeks prior to entry. * Comorbid conditions that would complicate safety or compliance